<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04980482</url>
  </required_header>
  <id_info>
    <org_study_id>AB-729-201</org_study_id>
    <nct_id>NCT04980482</nct_id>
  </id_info>
  <brief_title>Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection</brief_title>
  <official_title>A Randomized, Open-Label, Multicenter Study Investigating AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a Treatment in Subjects With Chronic Hepatitis B Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbutus Biopharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arbutus Biopharma Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open label, multicenter Phase 2 study investigating the safety and&#xD;
      antiviral activity of AB-729 in combination with ongoing NA therapy and short courses of&#xD;
      Peg-IFNα-2a in subjects with CHB.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The frequency and severity of treatment emergent adverse events (TEAEs), discontinuations due to adverse events (AEs), and laboratory abnormalities after dosing with AB-729 plus Peg-IFNα-2a</measure>
    <time_frame>Up to 124 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HBsAg and other virologic markers at each time point</measure>
    <time_frame>Up to 124 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with HBsAb seroconversion at each timepoint</measure>
    <time_frame>Up to 124 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who are eligible to stop NA after Week 24 of follow up</measure>
    <time_frame>Up to 76 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who discontinue NA and subsequently restart NA therapy after meeting criteria</measure>
    <time_frame>Up to 124 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who discontinue NA and subsequently meet protocol defined clinical relapse criteria. Proportion of subjects who discontinue NA and subsequently meet protocol defined viral relapse criteria</measure>
    <time_frame>Up to 124 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-dose plasma concentrations of AB-729 anti-sense (AS), AB-729 AS(N-1)3', and AB-729 AS(N-2)3' at selected timepoints</measure>
    <time_frame>Up to 40 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Chronic Hepatitis b</condition>
  <arm_group>
    <arm_group_label>Cohort A, Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to:&#xD;
AB-729 60 mg SC every 8 weeks + NA + Peg-IFNα-2a 180 mcg SC every week for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A, Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to:&#xD;
NA + Peg-IFNα-2a 180 mcg SC every week for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B, Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to:&#xD;
AB-729 60 mg SC every 8 weeks + NA + Peg-IFNα-2a 180 mcg SC every week for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B, Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AB-729 60 mg SC every 8 weeks + NA for 24 weeks, then randomized to:&#xD;
NA + Peg-IFNα-2a 180 mcg SC every week for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AB-729</intervention_name>
    <description>subcutaneous injection</description>
    <arm_group_label>Cohort A, Group 1</arm_group_label>
    <arm_group_label>Cohort A, Group 2</arm_group_label>
    <arm_group_label>Cohort B, Group 1</arm_group_label>
    <arm_group_label>Cohort B, Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peg-IFNα-2a</intervention_name>
    <description>subcutaneous injection</description>
    <arm_group_label>Cohort A, Group 1</arm_group_label>
    <arm_group_label>Cohort A, Group 2</arm_group_label>
    <arm_group_label>Cohort B, Group 1</arm_group_label>
    <arm_group_label>Cohort B, Group 2</arm_group_label>
    <other_name>pegylated interferon alpha 2a</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic hepatitis B virus infection with documentation at least 6 months prior to&#xD;
             screening&#xD;
&#xD;
          -  Subjects must have been receiving either TAF, TDF (or equivalent), or ETV consistently&#xD;
             for ≥12 months prior to dosing Day 1&#xD;
&#xD;
          -  HBV DNA &lt;LLOQ at Screening&#xD;
&#xD;
          -  HBsAg between 100 and 5,000 IU/mL at Screening&#xD;
&#xD;
          -  Subjects must be HBeAg-negative at Screening&#xD;
&#xD;
          -  Fibroscan® result of ≤8.5 kPa within 6 months prior to dosing Day 1&#xD;
&#xD;
          -  Medically stable based on physical examination, medical history, vital signs,&#xD;
             laboratory values, and 12-lead Electrocardiogram (ECG) at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of co-infection with hepatitis A, C, D or E virus or human immunodeficiency&#xD;
             virus (HIV) at screening&#xD;
&#xD;
          -  History of any clinically significant medical condition associated with chronic liver&#xD;
             disease, cirrhosis, evidence of decompensated liver disease, or findings suggestive of&#xD;
             hepatocellular carcinoma (HCC) at any time&#xD;
&#xD;
          -  Contraindications to the use of Peg-IFNα-2a or incapable of self-administration or&#xD;
             assisted administration of Peg-IFNα-2a&#xD;
&#xD;
          -  Previous treatment with an experimental HBV-directed RNA-interference or antisense&#xD;
             oligonucleotide product or Peg-IFNα-2a&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Arbutus Biopharma</last_name>
    <phone>267-469-0914</phone>
    <email>clinicaltrials@arbutusbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>ID Care</name>
      <address>
        <city>Hillsborough</city>
        <state>New Jersey</state>
        <zip>08844</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald Nahass, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ronald Nahass, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 19, 2021</study_first_submitted>
  <study_first_submitted_qc>July 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B virus</keyword>
  <keyword>Chronic hepatitis B</keyword>
  <keyword>HBV</keyword>
  <keyword>Hepatitis</keyword>
  <keyword>CHB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

